WASHINGTON, D.C. -- Medicare Part D premiums will see only a modest rise in 2017, despite costs to taxpayers growing faster than parts A and B, the Centers for Medicare and Medicaid Services (CMS) recently said in a statement. Read More »
SANUWAVE Health Inc. announced today that a de novo petition has been submitted to the U.S. Food and Drug Administration (FDA) asking for the review and classification of the dermaPACE System to be used in the treatment of Diabetic Foot Ulcers (DFU) as a Class II device. Read More »
BioCryst Pharmaceuticals announced this week that the APeX-1 clinical trial involving BCX7353, which is designed to treat hereditary angioedema (HAE), has begun with the first patient being dosed. Read More »
Asembia LLC, an industry leader in specialty pharmacy management company, recently unveiled its new HUB service and patient support program, which was developed as part of a partnership with MannKind Corp. and is designed for Afrezza Inhalation Powder. Read More »
The Washington Health Alliance recently released a report documenting that, on average, more than one in every 12 adults in Washington State covered by commercial insurance received at least one opioid prescription last year. Read More »
Walgreens this week announced the launch of its kiosks designated for the safe disposal of medications in Iowa. Read More »
Marken this week announced the official opening of a new GDP-compliant operations center in Switzerland. Read More »
Xbrane Biopharma recently announced that its subsidiary, Primm Pharma, has submitted an application for the GMP approval of its Spheroid production facility, located just outside of Naples, Italy, to the Italian Medicines Agency, AIFA. Read More »
MEI Pharma has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for Pracinostat, an investigational drug designed to treat newly diagnosed acute myeloid leukemia (AML) in combination with azacitidine in patients who are 75 years of age or older that are not healthy enough to receive intensive chemotherapy. Read More »
AcelRx Pharmaceuticals today reported topline results from its Phase III SAP302 clinical trial. Read More »
Zimmer Biomet Holdings Inc. has announced that it has acquired CD Diagnostics. Read More »
Paratek Pharmaceuticals today announced that it has begun its Phase III trial of omadacycline, which will study the drug’s effects on patients with acute bacterial skin and skin structure infections (ABSSSI). Read More »
ZINBRYTA, which was recently approved by the U.S. Food and Drug Administration (FDA), was developed to treat relapsing types of multiple sclerosis (MS) in adult patients. Read More »
Managing and monitoring the increasingly high cost of speciality drugs will be a key challenge to control insurance prices over the next two years, say employers and third party payers. Read More »
Second trial of cariprazine in treatment of MDD did not show significant changes versus placebo. Read More »
Continues expanding access to the opioid overdose reversal drug naloxone in all CVS Pharmacies. Read More »
Results of first annual general meeting of the health and wellness company announced. Read More »
Fexapotide produces positive results in two long-term Phase III clinical trials. Read More »
The American Pharmacists Association (APhA) Foundation recently announced the recipients of its 2016 Pinnacle Awards. Read More »
Cynapses Therapeutics Inc., a pharmaceutical company that specializes in the central nervous system (CNS), this week announced the completion of its Data Safety and Monitoring Board (DSMB) review of the safety data from its Phase III CTH-300 and CTH-301 clinical trials. Read More »
Alerts Sign-up